Marché de la biopsie liquide des cellules tumorales circulantes (CTC) au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et perspectives du marché : marché de la biopsie liquide des cellules tumorales circulantes (CTC) au Moyen-Orient et en Afrique

Le marché de la biopsie liquide des cellules tumorales circulantes (CTC) au Moyen-Orient et en Afrique devrait connaître une croissance du marché au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 16,7% au cours de la période de prévision de 2022 à 2029 et devrait atteindre 82,24 millions USD d'ici 2029 contre 24,50 millions USD en 2021. La forte prévalence des maladies chroniques et l'augmentation des activités de R&D pour son application efficace sont susceptibles d'être les principaux moteurs qui propulsent la demande du marché au cours de la période de prévision.

La biopsie liquide est un test sanguin non invasif qui détecte les cellules tumorales circulantes et les fragments d'ADN tumoral libérés dans le sang par les tumeurs primaires et les sites métastatiques. Il s'agit d'une alternative simple et précise à la biopsie chirurgicale, qui permet au chirurgien de détecter le cancer à un stade très précoce.

Les cellules tumorales circulantes sont un sous-ensemble rare de cellules qui fonctionnent comme germes de métastases. On les trouve dans le sang des patients qui ont développé des tumeurs solides. Le test des cellules tumorales circulantes permet la détection et la quantification des cellules tumorales dans le sang des patients atteints de cancer. Les différents types de phénotypes biologiques des cellules tumorales circulantes (CTC) comprennent les cellules souches ou mixtes, mésenchymateuses ou épithéliales. Ces phénotypes sont présents dans le sang en très petite quantité. C'est pourquoi leur détection nécessite une phase d'isolement-enrichissement. Ensuite, une deuxième phase de détection.

La demande croissante de biopsie liquide de cellules tumorales circulantes (CTC) en raison de leur efficacité et de la prévalence élevée du cancer sont les principaux facteurs qui propulsent la demande pour le marché de la biopsie liquide de cellules tumorales circulantes (CTC) au cours de la période de prévision. Cependant, le scénario réglementaire et de remboursement peu clair et la pénurie de personnel qualifié freinent la croissance du marché de la biopsie liquide de cellules tumorales circulantes (CTC) au cours de la période de prévision. 

The Middle East and Africa circulating tumor cells (CTC) liquid biopsy market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Market Size

Middle East and Africa circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of technology, circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies  In 2021, CTC detection methods segment is expected to dominate the market because of increasing use of this technology in the academics and research centers for the tests of liquid biopsy.
• On the basis of application, circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others. In 2021, cancer stem cell research segment is expected to dominate the market because of increasing demand of early diagnosis and treatment of cancer.
• On the basis of end user, circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories. In 2021, academic and research institutes segment is expected to dominate the market because of research and academic institutes perform an essential role to accelerate research and development in the various therapeutic area related to liquid biopsies.

Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Country Level Analysis

The Middle East and Africa circulating tumor cells (CTC) liquid biopsy market is analysed and market size information is provided by country, technology, application and end user.

The countries covered in the Middle East and Africa circulating tumor cells (CTC) liquid biopsy market report are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and Rest of the Middle East and Africa.

South Africa is expected to dominate the market because of high prevalence of chronic diseases such as cancer and increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market 

Middle East and Africa circulating tumor cells (CTC) liquid biopsy market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the circulating tumor cells (CTC) liquid biopsy market. The data is available for the historic period 2011 to 2019.

Competitive Landscape and Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Share Analysis

Middle East and Africa circulating tumor cells (CTC) liquid biopsy market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to circulating tumor cells (CTC) liquid biopsy market.

The major companies which are dealing in the circulating tumor cells (CTC) liquid biopsy market are Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, Guardant Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc.,  ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.

For instance,

• En août 2021, Exact Sciences Corporation a annoncé la mise en œuvre du test de biopsie liquide hépatique Oncogurard, qui offre une sensibilité de 82 % à un stade précoce et une spécificité de 87 %. Cela aidera l'entreprise à faire progresser ses travaux visant à vaincre le cancer grâce à une détection précoce.

La collaboration, les coentreprises et d'autres stratégies des acteurs du marché améliorent le marché de l'entreprise sur le marché de la biopsie liquide des cellules tumorales circulantes (CTC), ce qui offre également l'avantage à l'organisation d'améliorer son offre pour le marché de la biopsie liquide des cellules tumorales circulantes (CTC).

SKU-66918